Memantine Hydrochloride Tablet
Product Images NDC 27241-070

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 27241-070). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine-figure1 (Memantine Figure1)

A line graph comparing the mean change from baseline on the ADCS-ADL score over 28 weeks of treatment between Memantine Hydrochloride and placebo groups. The x-axis shows weeks of treatment (0, 4, 12, 28), and the y-axis shows mean change with error bars. Two lines represent treatment groups: placebo with squares and memantine with circles, showing differing trends in clinical improvement or decline.*

FDA Label Image

Memantine-figure3 (Memantine Figure3)

A line graph comparing the mean change from baseline in SIB scores over 28 weeks of treatment between placebo and Memantine Hydrochloride groups. The graph shows weeks of treatment on the x-axis and mean change with SEM on the y-axis, indicating trends toward clinical improvement or decline for each group.*

FDA Label Image

Memantine-figure5 (Memantine Figure5)

A line graph showing the mean change from baseline in ADCS-ADL scores over 24 weeks of treatment comparing Memantine Hydrochloride/Donepezil versus Placebo/Donepezil. The x-axis represents weeks of treatment, and the y-axis represents the mean change with error bars. Memantine Hydrochloride/Donepezil group shows lesser decline, trending towards clinical improvement, while Placebo/Donepezil shows greater clinical decline over time.*

FDA Label Image

Memantine-figure7 (Memantine Figure7)

A line graph depicting the mean change from baseline in SIB scores over 24 weeks of treatment comparing Memantine Hydrochloride/Donepezil and Placebo/Donepezil. The y-axis shows mean change (± SEM) while the x-axis represents treatment weeks. Memantine Hydrochloride/Donepezil shows an increase indicating clinical improvement, whereas Placebo/Donepezil shows decline over time.*

FDA Label Image

Memantine_structure (Memantine Structure)

Chemical structure of Memantine Hydrochloride showing the molecular arrangement including amino group (NH2) and methyl groups attached to the cage-like adamantane framework.*

FDA Label Image

Memantine-10mg (Memantine 10mg)

Memantine Hydrochloride Tablets 10 mg film-coated tablets packaging label. The label indicates a package of 60 tablets, marketed by Ajanta Pharma USA Inc., Bridgewater, NJ. It includes storage instructions and a barcode on the right side. The label also notes the product is prescription only and made in India.*

FDA Label Image

Memantine-5mg (Memantine 5mg)

Memantine Hydrochloride 5 mg tablets label for a 60-tablet prescription bottle. The film-coated tablets contain 5 mg of Memantine Hydrochloride USP. The label includes storage instructions, child-resistant packaging notice, and marketing by Ajanta Pharma USA Inc., Bridgewater, NJ. Made in India.*

FDA Label Image

Memantine-figure2 (Memantine Figure2)

A line graph comparing the cumulative percentage of patients against the ADCS-ADL change from baseline for Memantine Hydrochloride and a placebo. The x-axis represents changes from baseline, and the y-axis shows the cumulative percentage of patients, illustrating a higher proportion of patients improving with Memantine Hydrochloride compared to placebo.*

FDA Label Image

Memantine-figure4 (Memantine Figure4)

A cumulative percentage graph showing patient response comparing Memantine Hydrochloride and placebo. The x-axis represents SIB change from baseline, while the y-axis displays the cumulative percentage of patients. The graph uses square markers for placebo and circular markers for Memantine Hydrochloride treatment.*

FDA Label Image

Memantine-figure6 (Memantine Figure6)

A line graph showing cumulative percentage of patients on the vertical axis and ADCS-ADL change from baseline on the horizontal axis. Two curves compare the effects of Placebo/Donepezil and Memantine hydrochloride/Donepezil on patient outcomes.*

FDA Label Image

Memantine-figure8 (Memantine Figure8)

A line graph comparing the cumulative percentage of patients versus SIB change from baseline. It shows two curves, one for Placebo/Donepezil and one for Memantine Hydrochloride/Donepezil, illustrating patient response over a range of changes in SIB scores.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.